Andrew Filderman is a Respiratory physician. OpenAlex indexes 25 publications with 540 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4 Glen Cove Drive
Suite 200
Rockport, ME 04856
Telephone
207-301-3060Registry record last updated 21 Mar 2025.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year202511 payments
- JAZZ PHARMACEUTICALS INC.Program year20252 payments
- GENZYME CORPORATIONProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
76.4%Corticosteroid44.8%Trelegy Ellipta34%Breo Ellipta30%Symbicort12%Breztri Aerosphere12%Arnuity Ellipta6%Budesonide-Formoterol Fumarate2%Breyna2%Fluticasone Propionate2%Part D<11 patientsbeta2-Adrenergic Agonist20%Albuterol Sulfate Hfa92%Ventolin Hfa8%Part D≥132 patients+ 4 more classes in this area
Metabolism & gastrointestinal
12%Corticosteroid12%Prednisone100%Part D≥102 patientsAnti-infectives
7.9%Macrolide Antimicrobial3.8%Azithromycin100%Part D≥52 patientsTetracycline-class Drug2.3%Doxycycline Hyclate100%Part D≥31 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines.
PubMed
1992 - Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
PubMed
1992
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”